Danielle Lauzon is a partner in Goodwin’s Technology and Life Sciences groups, and leader of the firm’s Business Law department in Boston. Danielle currently serves on Goodwin’s Partnership Committee.
Danielle advises privately-held and publicly-traded companies across the company life-cycle, including formation and founder matters, venture capital and growth equity financings, public offerings, mergers and acquisitions, joint ventures, carve-out transactions, SEC compliance and corporate governance. In addition, Danielle represents venture capital and private equity firms in connection with their investments in emerging growth and later-stage companies. Danielle’s practice focuses on the life sciences and healthcare sectors, including biotechnology, medical devices, digital health, healthcare IT, health & wellness and women’s health.
Danielle acts as co-chair of Goodwin’s PropSci practice which is focused on supporting the intersection of life sciences and real estate by providing clients integrated and innovative services that adapt along with their needs.
Experience
- Third Arc Bio in its $165 million Series A financing
- Renagade Therapeutics in its $300 million Series A financing
- ElevateBio in its $401 million Series D financing
- ElevateBio in its $525 million Series C financing
- ElevateBio in its $170 million Series B financing
- Alltrna in $109 million Series B financing
- Insight Partners in connection with its investments in Autobahn Therapeutics, Capacity Bio, Exsilio Therapeutics, ImmuneBridge, Profluent, Superluminal, Switch Therapeutics and Syrna Therapeutics
- Cure Ventures in the $82 million Series A financing of Kenai Therapeutics
- Laronde in its $440 million Series B financing
- Instride Health in its $30 million Series B financing
- FamilyWell Health in its $4.3 million Series Seed financing
- Koneksa Health in its $45 million Series C financing
- Koneksa Health in its $16 million Series B financing
- .406 Ventures in its investments in Iora Health, Heartbeat Health, Wellist, Virtudent, Diana Health, Portrait Analytics, and Vivorcare
- Flare Capital in its investments in Eden Health, Greater Good Health, Inbound Health, Oui Health and Positive Development
- HLM Venture Partners in its investment in HealthEC
- Aura Biosciences in its $80 million financing
- Cullinan Oncology in its $131.2 million Series C financing
- Unum Therapeutics in its $104.4 million private placement of common stock
- Outcomes4Me in its Series Seed and Series A preferred stock financings
- iTeos Therapeutics in its $125.3 million Series B financing
- Allurion Technologies in its $27 million Series C financing
- Omega Funds in its investments in Amunix Pharmaceuticals, Endeavor BioMedicines and Vanqua Bio
- AbleTo, Inc. in its Series A, Series B, Series C, and Series D financings
- Moderna Therapeutics in the closing of a $110 million financing round
- Alector LLC in its Series A, Series B, Series C, and Series D financings
- Unum Therapeutics in its $65 million Series B financing
- Adicet Bio in its $100.0 million at-the-market offering
- Adicet Bio in its $90.0 million public offering
- Adicet Bio in its $87.5 million public offering
- Adicet Bio in its $130 million public offering and concurrent $15 million private placement
- Blueprint Medicines Corporation in its $325 million follow-on offering
- Blueprint Medicines in its $345 million, $230 million and $125 million follow-on offerings
- BELLUS Health in its $200 million public offering
- BELLUS Health in its $40 million public offering
- Aura Biosciences in its $99.0 million public offering
- Aura Biosciences in its $80.4 million public offering
- Aura Biosciences in its $75.6 million initial public offering
- iTeos Therapeutics in its $201.1 million initial public offering
- AlloVir, Inc. in its $317.7 million initial public offering
- resTORbio, Inc. in its $97.8 million initial public offering
- Cullinan Oncology in its $249.9 million initial public offering
- Unum Therapeutics in its $69.2 million initial public offering and $5 million concurrent private placement
- ProQR Therapeutics in its $75 million underwritten public offering
- ProQR Therapeutics in its $20 million underwritten public offering and concurrent registered direct offering
- ProQR Therapeutics N.V. in its $97.5 million initial public offering
- Zafgen in its $60 million underwritten public offering
- Aerpio Pharmaceuticals in its $40 million underwritten public offering and uplisting to Nasdaq
- Aerpio Pharmaceuticals in its $75 million at-the-market program with Cantor Fitzgerald & Co.
- Blueprint Medicines in its acquisition of Lengo Therapeutics
- Allurion Technologies in its business combination with Compute Health Acquisition Corp.
- Unum Therapeutics in its acquisition of KIQ and concurrent private placement
- Aerpio Pharmaceuticals in its reverse merger with Aadi Biosciences and concurrent private placement
- Zafgen in its definitive merger agreement with Chondrial Therapeutics
- resTORbio, Inc. in its reverse merger with Adicet Bio
- Semma Therapeutics in its $950 million sale to Vertex
- Navitor Pharmaceuticals in connection with the sale of Anakuria Therapeutics by Janssen Pharmaceuticals
- Onyx Pharmaceuticals in its $10.4 billion sale to Amgen
- AMRI in its $1.7 billion (enterprise value) sale to affiliates of The Carlyle Group and GTCR LLC
- AMRI in its $358 million acquisition of Euticals and $174 million acquisition of Gadea Pharmaceutical Group
- Promedior, Inc. in its strategic agreement with Bristol-Myers Squibb
- Picis Solutions in its sale to Ingenix, a subsidiary of UnitedHealth Group
- Phase Forward in its sale to Oracle Corporation
Professional Activities
Danielle is a member of the Massachusetts and Boston Bar Associations.
Professional Experience
Prior to joining Goodwin, Danielle was an associate in the Business Practice Group at Testa, Hurwitz & Thibeault in Boston.
Credentials
Education
JD2000
Villanova University School of Law
(magna cum laude, Order of the Coif)
BA1997
University of Michigan
Admissions
Bars
- Massachusetts
Recognition & Awards
Danielle is most recently recognized by Chambers USA 2024 in Massachusetts Private Equity: Venture Capital Investment.
Danielle has been recognized by The Legal 500 US for her work in the life science industry and in 2023 as a Next Generation Partner in Venture Capital and Emerging Companies. Massachusetts Lawyers Weekly named Danielle to its Top Women of Law list for 2021. From 2007 through 2021, she was recognized as a Massachusetts Super Lawyer "Rising Star" by Law & Politics and Boston magazine. In law school, Danielle was a member of the Villanova Law Review.